TradingKey

關於 Liquidia Corp 公司

Liquidia Corporation 是一家生物製藥公司。該公司專注於開發、製造和商業化滿足未滿足患者需求的產品，重點是罕見的心肺疾病，例如肺動脈高壓 (PAH) 和與間質性肺病相關的肺動脈高壓 (PH-ILD)。該公司通過其全資運營子公司 Liquidia Technologies, Inc. 和 Liquidia PAH, LLC 開展業務。其專有的 PRINT 技術是一種粒子工程平臺，可精確生產均勻的藥物顆粒。其主要候選產品是用於治療 PAH 和 PH-ILD 的 YUTREPIA。YUTREPIA 是一種吸入式曲前列尼爾乾粉製劑，採用 PRINT 設計，通過增強深肺輸送，同時使用方便的乾粉吸入器 (DPI) 並實現比當前吸入療法標示劑量更高的劑量水平，從而改善曲前列尼爾的治療特性。

公司簡介

公司代碼LQDA

公司名稱Liquidia Corp

上市日期Jul 26, 2018

CEODr. Roger A. Jeffs, Ph.D.

員工數量157

證券類型Ordinary Share

年結日Jul 26

公司地址419 Davis Drive

城市MORRISVILLE

上市交易所NASDAQ Capital Market Consolidated

國家United States of America

郵編27560

電話19193284400

網址https://www.liquidia.com/

公司代碼LQDA

上市日期Jul 26, 2018

CEODr. Roger A. Jeffs, Ph.D.

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Roger A. Jeffs, Ph.D.

Chief Executive Officer, Director

2.12M

-0.30%

Mr. Russell Schundler, J.D.

General Counsel, Secretary

368.64K

-1.09%

Mr. Rajeev Saggar, M.D.

Chief Medical Officer

262.60K

-1.62%

Mr. Scott Moomaw

Chief Commercial Officer

214.39K

-0.78%

Mr. Jason Adair

Chief Business Officer

161.37K

-0.34%

Mr. Michael Kaseta

Chief Financial Officer, Chief Operating Officer

110.59K

-21.34%

Mr. Damian Degoa

Independent Director

66.11K

+38.55%

Mr. Arthur S. Kirsch

Independent Director

50.40K

+57.49%

Dr. Joanna C. Horobin

Independent Director

18.40K

--

Ms. Katherine (Katie) Rielly-Gauvin

Independent Director

18.40K

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Roger A. Jeffs, Ph.D.

Chief Executive Officer, Director

2.12M

-0.30%

Mr. Russell Schundler, J.D.

General Counsel, Secretary

368.64K

-1.09%

Mr. Rajeev Saggar, M.D.

Chief Medical Officer

262.60K

-1.62%

Mr. Scott Moomaw

Chief Commercial Officer

214.39K

-0.78%

Mr. Jason Adair

Chief Business Officer

161.37K

-0.34%

Mr. Michael Kaseta

Chief Financial Officer, Chief Operating Officer

110.59K

-21.34%

收入明細

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

暫無數據

地區USD

名稱

營收

佔比

United States

14.00M

0.00%

業務

地區

暫無數據

股東統計

更新時間: 8月13日週三

持股股東

股東類型

持股股東

佔比

Caligan Partners, LP

9.43%

Farallon Capital Management, L.L.C.

7.94%

Manning (Paul B.)

7.16%

BlackRock Institutional Trust Company, N.A.

4.95%

The Vanguard Group, Inc.

4.16%

Other

66.36%

持股股東

佔比

Caligan Partners, LP

9.43%

Farallon Capital Management, L.L.C.

7.94%

Manning (Paul B.)

7.16%

BlackRock Institutional Trust Company, N.A.

4.95%

The Vanguard Group, Inc.

4.16%

Other

66.36%

股東類型

持股股東

佔比

Hedge Fund

35.47%

Investment Advisor

16.61%

Investment Advisor/Hedge Fund

11.95%

Individual Investor

11.87%

Research Firm

3.52%

Corporation

2.69%

Private Equity

1.78%

Bank and Trust

0.41%

Pension Fund

0.22%

Other

15.47%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

350

67.92M

79.46%

-5.32M

2025Q1

356

67.75M

79.47%

-4.91M

2024Q4

344

63.62M

75.17%

-10.09M

2024Q3

335

73.31M

89.39%

+16.42M

2024Q2

318

66.67M

87.88%

+4.98M

2024Q1

302

59.34M

79.61%

+7.64M

2023Q4

256

48.15M

70.41%

+4.56M

2023Q3

236

40.52M

62.49%

-5.87M

2023Q2

223

41.12M

63.56%

-6.16M

2023Q1

214

42.01M

65.00%

-5.41M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Caligan Partners, LP

8.12M

9.5%

--

Apr 23, 2025

Farallon Capital Management, L.L.C.

3.99M

4.67%

+700.00K

+21.27%

Mar 31, 2025

Manning (Paul B.)

6.16M

7.21%

+18.40K

+0.30%

Jun 17, 2025

BlackRock Institutional Trust Company, N.A.

4.20M

4.91%

+14.68K

+0.35%

Mar 31, 2025

The Vanguard Group, Inc.

3.45M

4.04%

-94.77K

-2.67%

Mar 31, 2025

Findell Capital Management LLC

2.89M

3.38%

-190.00K

-6.17%

Mar 31, 2025

Opaleye Management Inc.

2.26M

2.64%

+561.86K

+33.09%

Mar 31, 2025

Jeffs (Roger A)

2.13M

2.49%

+38.56K

+1.85%

Jun 04, 2025

Legend Aggregator LP

1.86M

2.18%

-5.32M

-74.10%

Dec 31, 2024

State Street Global Advisors (US)

1.79M

2.09%

-24.05K

-1.33%

Mar 31, 2025

持股ETF

更新時間: 8月6日週三

機構名稱

佔比

SPDR S&P Pharmaceuticals ETF

2.16%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.34%

Virtus LifeSci Biotech Clinical Trials ETF

0.78%

iShares U.S. Pharmaceuticals ETF

0.44%

First Trust Small Cap Growth AlphaDEX Fund

0.19%

iShares Micro-Cap ETF

0.18%

SPDR S&P Kensho New Economies Composite ETF

0.16%

First Trust Small Cap Core Alphadex Fund

0.1%

iShares Russell 2000 Growth ETF

0.05%

iShares ESG Aware MSCI USA Small-Cap ETF

0.04%

SPDR S&P Pharmaceuticals ETF

佔比2.16%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.34%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.78%

iShares U.S. Pharmaceuticals ETF

佔比0.44%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.19%

iShares Micro-Cap ETF

佔比0.18%

SPDR S&P Kensho New Economies Composite ETF

佔比0.16%

First Trust Small Cap Core Alphadex Fund

佔比0.1%

iShares Russell 2000 Growth ETF

佔比0.05%

iShares ESG Aware MSCI USA Small-Cap ETF

佔比0.04%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Liquidia Corp

25.200USD

Liquidia Corp

25.200

概覽

公司

財務